Compelo Medical Devices is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More
Close
Dismiss

Progenra, Ono Pharma in research collaboration agreement

Progenra has entered into a research collaboration agreement with Ono Pharmaceutical.

Progenra will collaborate with Ono to conduct assay development and screening by using its proprietary technology on multiple targets in the ubiquitin pathway, as per the agreement.

Progenra utilizes its UbiProDrug Discovery Platform to identify modulators of tractable targets in the ubiquitin proteasome pathway with the goal of developing drugs.

The pathway plays a vital role in the regulation of protein metabolism within the cell, as determining the fate of proteins by either targeting them for destruction by the proteasome or preserving them from this fate.